So-Young International (NASDAQ:SY – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03, Zacks reports. The company had revenue of $62.77 million during the quarter, compared to analysts’ expectations of $60.20 million. So-Young International had a negative net margin of 15.97% and a negative return on equity of 12.54%.
Here are the key takeaways from So-Young International’s conference call:
- So-Young reported Q1 2026 revenue of RMB 432.8 million, up 45.6% year over year, with aesthetic treatment services revenue rising 185.8% to RMB 282.4 million and exceeding the high end of guidance for the fourth straight quarter.
- The company’s clinic chain continued to scale quickly, reaching 59 centers across 17 cities by today, with Q1 treatment visits up 172% year over year and verified treatments up 164% year over year.
- Unit economics improved further, with 41 centers profitable and 48 generating positive operating cash flow in Q1. Management also said the aesthetic center business gross margin reached 27%, reflecting better operating efficiency.
- Management highlighted strong user engagement, including core members above 63,000 and referral-sourced new customers rising to 52% of the mix, while emphasizing that CAC remained well controlled.
- The company raised its supply-chain and product strategy, including an exclusive partnership with Jinbo Bio-Pharmaceutical and the launch of Miracle Collagen, while blockbuster products such as BBL and Thermage lifted blockbuster-product revenue contribution to 41% of Q1 sales.
So-Young International Price Performance
Shares of So-Young International stock opened at $2.23 on Friday. So-Young International has a 1 year low of $0.82 and a 1 year high of $6.28. The firm has a market cap of $226.19 million, a PE ratio of -6.19 and a beta of 2.10. The company has a 50 day simple moving average of $2.86 and a two-hundred day simple moving average of $3.00.
Analysts Set New Price Targets
View Our Latest Stock Analysis on So-Young International
Institutional Investors Weigh In On So-Young International
Several hedge funds have recently bought and sold shares of SY. Barclays PLC lifted its position in So-Young International by 124.3% during the fourth quarter. Barclays PLC now owns 1,116,336 shares of the company’s stock valued at $2,858,000 after purchasing an additional 618,709 shares during the last quarter. Nomura Holdings Inc. bought a new stake in So-Young International during the third quarter valued at approximately $1,265,000. Lighthouse Investment Partners LLC bought a new stake in So-Young International during the third quarter valued at approximately $1,105,000. Quadrature Capital Ltd bought a new stake in So-Young International during the third quarter valued at approximately $1,080,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in So-Young International during the third quarter valued at approximately $663,000. 35.31% of the stock is currently owned by institutional investors.
So-Young International Company Profile
So-Young International Inc operates a leading digital marketplace and community platform focused on the medical aesthetic industry in China. Headquartered in Shanghai and founded in 2013, the company connects consumers seeking cosmetic treatments with a network of accredited clinics, licensed physicians and beauty service providers. Its online ecosystem offers a wealth of educational content, peer reviews and before-and-after galleries designed to help users make informed decisions about aesthetic procedures.
The company’s platform is accessible via web and mobile applications, where users can browse service packages, compare providers, read expert articles and schedule appointments directly through an integrated booking system.
Further Reading
- Five stocks we like better than So-Young International
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for So-Young International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for So-Young International and related companies with MarketBeat.com's FREE daily email newsletter.
